Antipsychotic treatment in schizophrenia: Atypical options and NICE guidance

European Psychiatry

Volumn 18, Issue 5, 2003, Pages 209-219

  Mortimer, Ann M ^a  

^a UNIVERSITY OF HULL   (United Kingdom)

Author keywords

Atypical antipsychotic; NICE guidance; Novel drug discovery; Schizophrenia; Side effects

Indexed keywords

2,3,3A,12B TETRAHYDRO 3 METHYL 1H DIBENZO[B,F]OXEPINO[10,11 C]PYRROLE; 3 [3 (METHYLSULFONYL)PHENYL] 1 PROPYLPIPERIDINE; 6 QUINOXALINECARBOXYLIC ACID PIPERIDIDE; ALPHA (2,3 DIMETHOXYPHENYL) 1 [2 (4 FLUOROPHENYL)ETHYL] 4 PIPERIDINEMETHANOL; ALPHA [1 [2 (1,4 BENZODIOXAN 5 YLOXY)ETHYL] 3 PYRROLIDINYL] 4 FLUOROACETOPHENONE; AMISULPRIDE; ARIPIPRAZOLE; BIFEPRUNOX; CLOZAPINE; DOPAMINE 2 RECEPTOR BLOCKING AGENT; DOPAMINE 3 RECEPTOR STIMULATING AGENT; DTA 201; EPLIVANSERIN; FLUOXETINE; HALOPERIDOL; ILOPERIDONE; NEFAZODONE; OLANZAPINE; OSANETANT; QUETIAPINE; RISPERIDONE; SEROTONIN 1A AGONIST; SEROTONIN ANTAGONIST; SERTINDOLE; SONEPIPRAZOLE; THIORIDAZINE; UNCLASSIFIED DRUG; ZIPRASIDONE; ZOTEPINE;

ABDOMINAL PAIN; AGITATION; AKATHISIA; ANXIETY DISORDER; CLINICAL FEATURE; CLINICAL TRIAL; DIABETES MELLITUS; DRUG EFFICACY; DRUG FORMULATION; DRUG RECEPTOR BINDING; DRUG RELEASE; DRUG SAFETY; DRUG TOLERABILITY; EXTRAPYRAMIDAL SYMPTOM; GASTROINTESTINAL SYMPTOM; GLUCOSE METABOLISM; HEART ARRHYTHMIA; HEART DISEASE; HUMAN; HYPERPROLACTINEMIA; INSOMNIA; MONOTHERAPY; NEUTROPENIA; ORTHOSTATIC HYPOTENSION; PATIENT COMPLIANCE; PRIORITY JOURNAL; QT INTERVAL; RELAPSE; REVIEW; SCHIZOPHRENIA; SEDATION; SEXUAL DYSFUNCTION; SIDE EFFECT; SOMNOLENCE; VERTIGO; WEIGHT GAIN; XEROSTOMIA;

EID: 0041471142     PISSN: 09249338     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0924-9338(03)00060-9     Document Type: Article

References (153)

1. Adams C, The Cochrane Schizophrenia Group. Drug treatments for schizophrenia, 5. NHS Centre for Reviews and Dissemination; 1999 Effective Health Care [report].
2. Allison DB, Mentmore JL, Heo M, Chandler LP, Cappelleri JC, Infante MC, et al. Antipsychotic-induced weight gain: a comprehensive research synthesis. Am J Psychiatry 1999;156(11):1686-96.
3. Ames D, Wirshing WC, Marshall BD. Risperidone versus haloperidol in treatment resistant schizophrenia. Schizophrenia Res 1997;24:193-4.
4. Arvanitis LA, Miller BG, the Seroquel Trial Study Group. Multiple fixed doses of 'Seroquel' (quetiapine) in patients with acute exacerbation of schizophrenia: a comparison with haloperidol and placebo. Biol Psychiatry 1997;42:233-46.
5. Bahr BA, Bendiske J, Brown QB, Munirathinam S, Caba E, Rudin M, et al. Survival signaling and selective neuroprotection through glutamatergic transmission. Exp Neurol 2002;74(1):37-47.
6. Barnas C, Stuppack CH, Miller C, Haring C, Sperner-Unterweger B, Fleischhacker WW. Zotepine in the treatment of schizophrenic patients with prevailingly negative symptoms, a double blind trial versus haloperidol. Int Clin Psychopharmacol 1992;7:23-7.
7. Barnes TRE, Edwards J. Antipsychotic drugs and their side effects. London: Academic Press; 1993.
8. Barnett D. Guidance on the use of newer (atypical) antipsychotic drugs for the treatment of schizophrenia, 43. London: National Institute for Clinical Excellence; 2002 Technology Appraisal Guidance [report].
9. Beasley CM, Hamilton SH, Crawford AM. Olanzapine versus haloperidol: acute-phase results of the international double-blind olanzapine trial. Eur Neuropsychopharmacol 1997;7:125-37.
10. Beasley CM, Tollefson G, Tran P. Olanzapine versus haloperidol and placebo: acute phase results of the North American double-blind olanzapine trial. Neuropsychopharmacology 1996;14:111-24.
11. Biswasl PN, Wilton LV, Pearcel GL, Freemantle S, Shakir SA. The pharmacovigilance of olanzapine: results of a post-marketing surveillance study on 8858 patients in England. J Psychopharmacol 2001; 15(4):265-71.
12. Blin O. Which role for amisulpride in rehabilitation of schizophrenic patients with acute exacerbation? Encephale 2000;26(Spec No 1): 7-11.
13. Bondolfi G, Baumann P, Dufour H. Treatment resistant schizophrenia: experience with new antipsychotics. Eur Neuropsychopharmacol 1996;6(Suppl 2):2-25.
14. Borison RL, Arvanitis LA, Miller BG. A comparison of five fixed doses of 'Seroquel' (ICI 204, 636) with haloperidol and placebo in patients with schizophrenia. Schizophrenia Res 1996;18(2,3):132.
15. Borison RL, Arvanitis LA, Miller BG, et al. ICI 204,636, an atypical antipsychotic: efficacy and safety in a multicenter, placebo-controlled trial in patients with schizophrenia. J Clin Psychopharmacol 1996; 16: 158-69.
16. Boyer P, Lecrubier Y, Peuch AJ. Treatment of negative symptoms in schizophrenia with amisulpiride. Br J Psychiatry 1995;166:68-72.
17. Breier A, Buchanan JR, Kirkpatrick B. Effects of clozapine on positive and negative symptoms in outpatients with schizophrenia. Am J Psychiatry 1994;151:20-6.
18. Buchanan RW, Kreyenbuhl J, Zito JM, Lehman A. Relationship of the use of adjunctive pharmacological agents to symptoms and level of function in schizophrenia. Am J Psychiatry 2002;159(6):1035-43.
19. Buse JB. Metabolic side effects of antipsychotics: focus on hyperglycaemia and diabetes. J Clin Psychiatry 2002;63(Suppl 4):37-41.
20. Caliguiri M, Lohr JB, Jeste DV. Parkinsonism in neuroleptic naive schizophrenic patients. Am J Psychiatry 1993;150(9):1343-8.
21. Cavazzoni P, Baker RW, Kwong K, Hornbuckle K, Hutchins D, Jovanovic L, et al. A pharmacoepidemiological study of diabetes mellitus and antipsychotic treatment in the United States [pamphlet]. 2002.
22. Clark O, O'Carroll R. An examination of the relationship between executive function and rehabilitation status in schizophrenia. Neuropsycholog Rehabilitat 2003 (in press).
23. Conley R, Love R, Kelly DL, Bartko JJ. Rehospitalisation rates of patients recently discharged on a regimen of risperidone or clozapine. Am J Psychiatry 1999;156:863-8.
24. Conley R, Tamminga CA, Bartko JJ, Richardson C, Peszke M, Lingle J, et al. Olanzapine compared with chlorpromazine in treatment-resistant schizophrenia. Am J Psychiatry 1998;155(7): 914-20.
25. Cooper SJ, Butler A, Tweed J, Welch C, Raniwalla J. Zotepine in the prevention of recurrence: a randomised, double-blind, placebo-controlled study for chronic schizophrenia. Psychopharmacology 2000;150(3):237-43.
26. Cooper SJ, Tweed J, Raniwalla J, Butler A, Welch C. A placebo-controlled comparison of zoptepine versus chlopromazine in patients with acute exacerbation of schizophrenia. Acta Psychiatr Scand 2000; 101(3):218-25.
27. Coukell AJ, Spencer CM, Benfield P. Amisulpiride: a review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the management of schizophrenia. CNS Drugs 1996;6(3): 237-56.
28. Csernansky JG. A comparison of risperidone and haloperidol for the prevention of relapse in patients with schizophrenia. N Engl J Med 2002;346(1):16-22.
29. Cummins C, Stevens A, Kisely C. In: Milne R, Stein K, editors. The use of olanzapine as a first and second choice treatment in schizophrenia, 84. 1998. p. 1-50 The South and West Development and Evaluation Service [report].
30. Currier GW, Simpson GM. Risperidone liquid concentrate and oral lorazepam versus intramuscular haloperidol and intramuscular lorazepam for treatment of psychotic agitation. J Clin Psychiatry 2001;62(3):153-7.
31. Czekalla J, Kollach-Walker S, Beasley CM. Cardiac safety parameters of olanzapine: comparison with other atypical and typical antipsychotics. J Clin Psychiatry 2001;62(Suppl 2):35-40.
32. Dannion J, Rein W, Fleurot O. Improvement of schizophrenic patients with primary negative symptoms treated with amisulpiride. Am J Psychiatry 1999;156:610-6.
33. Davis JM, Schaffer CB, Killian GA. Important issues in the drug treatment of schizophrenia. Schizophrenia Bull 1980;6:70-87.
34. Davis R, Janicak PG. Risperidone: a new, novel (and better?) antipsychotic. Psychiatric Ann 1996;26:78-87.
35. de Paulis T. M-100907 (Aventis). Curr Opinion Investigation Drugs 2001;2(1):123-32.
36. Decina P, Mukherjee S, Bocola V. Adjunctive trazodone in the treatment of negative symptoms of schizophrenia. Hosp Community Psychiatry 1994;45:1220-3.
37. Dev V, Raniwalla J. Quetiapine: a review of its safety in the management of schizophrenia. Drug Safety 2000;23(4):295-307.
38. Dose M, Tempel HD. Abuse potential on anticholinergics. Pharmacopsychiatry 2000;33(Suppl 1):43-6.
39. Dwyer DS, Bradley RJ, Kablinger AS, Freeman 3 AM. Glucose metabolism in relation to schizophrenia and antipsychotic drug treatment. Ann Clin Psychiatry 2001;13(2):103-13.
40. Ekesbo A, Andren PE, Gunne LM, Tedroff J. (-)-OSU 6162 inhibits levodopa-induced dyskinesias in a monkey model of Parkinson's disease. Neuroreport 1997;8(11):2567-70.
41. Ekesbo A, Torstenson R, Hartvig P, Carlsson A, Sonesson C, Waters N, et al. Effects of the substituted (S)-3-phenylpiperidine (-)-OSU6162 on PET measurements of [11C] SCH23390 and [11C] raclopride binding in primate brains. Neuropharmacology 1999;38(3):331-8.
42. Emsley RA, Raniwalla J, Bailey PJ, Jones AM. A comparison of the effects of quetiapine ('Seroquel') and haloperidol in schizophrenic patients with a history of and a demonstrated, partial response to conventional antipsychotic treatment. Int Clin Psychopharmacol 2000;15:121-31.
43. Falsetti AE. Risperidone for control of agitation in dementia patients. Am J Health-System Pharmacy 2000;57(9):862-70.
44. Farde L, Wiesel FA, Halldin C. Central dopamine-2 occupancy in schizophrenic patients treated with antipsychotic drugs. Arch General Psychiatry 1988;45:71-6.
45. Finn C. Risperdal long acting microspheres. In: Mortimer AM, editor. 2001 26-9-2001 [personal communication].
46. Freeman HL. Amisulpiride compared with standard neuroleptics in acute exacerbations of schizophrenia: three efficacy studies. Int Clin Psychopharmacol 1997;12(Suppl 2):11-7.
47. Geddes J, Freemantle N, Harrison P, Bebbington P. Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis. Br Med J 2000;321:1371-6.
48. Glassman AH, Bigger JT. Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death. Am J Psychiatry 2001; 158(11):1774-82.
49. Goff DC, Leahy I, Berman I, Posever T, Herz L, Leon AC, et al. A placebo-controlled study of the ampakiine CX516 added to clozapine in schizophrenia. J Clin Psychopharmacol 2001;21(5):484-7.
50. Goff DC, Posever T, Herz L, Simmons J, Kletti N, Lapierre K, et al. An exploratory haloperido-controlled dose-finding study of ziprasidone in hospitalised patients with schizophrenia or schizoaffective disorder. J Clin Psychopharmacol 1998;18(4):296-304.
51. Green B. Focus on risperidone. Curr Med Res Opinion 2000; 16(2): 57-65.
52. Gunasekara NS, Spencer CM, Keating GM. Ziprasidone: a review of its use in schizophrenia and schizoaffective disorder. Drugs 2002; 62(8):1217-51.
53. Gunn KP. Ziprasidone: safety and efficacy. Schizophrenia Res 1996; 18:132-3.
54. Haddad P. QTc prolongation and schizophrenia: managing the risks. Progr Neurology Psychiatry 2001(Suppl):2-11.
55. Haupt DW, Newcomer J. Hyperglycaemia and antipsychotic medications. J Clin Psychiatry 2001;62(Suppl 27):15-26.
56. Hellewel JSE. Efficacy of quetiapine in aggression and hostility in schizophrenia. Presented at the Association of European Psychiatry Congress, 1998. 1998.
57. Hellewel JSE, Kalati A, Langham S, McKellar J. Patients' satisfaction and acceptability of long-term treatment with 'seroquel': results of an international study. Presented at the ECNP, 1997. 1997.
58. Henderson DC. Atypical antipsychotic-induced diabetes mellitus: how strong is the evidence? CNS Drugs 2002;16(2):77-89.
59. Henderson DC, Cagliero E, Gray C, Nasrallah HA, Hayden DL, Schoenfeld DA. Clozapine, diabetes mellitus, weight gain, and lipid abnormalities: a five-year naturalistic study. Am J Psychiatry 2000; 157:975-81.
60. Hwang TJ, Lin SK, Lin H-N. Efficacy and safety of zotepine for the treatment of Taiwanese schizophrenic patients: a double-blind comparison with haloperidol. J Formosan Med Assoc 2001;100(12):811-6.
61. Jain KK. An assessment of iloperidone for the treatment of schizophrenia. Expert Opinion Investigation Drugs 2000;9(12):2935-43.
62. Joffe G, Appelberg B, Rimon R. Adjunctive nefazodone in neuroleptic-treated schizophrenic patients with predominantly negative symptoms: an open prospective pilot study. Int Clin Psychopharmacol 1999;14:233-8.
63. Johnson SA, Luu NT, Herbst TA, Knapp R, Lutz D, Arai A, et al. Synergistic interactions between ampakines and antipsychotic drugs. J Pharmacol Exp Ther 1999;289(1):392-7.
64. Johnstone EC, Crow TJ, Ferrier IN, Frith CD, Owens DGC, Bourne RC, et al. Adverse effects of anticholinergic medication on positive schizophrenic symptoms. Psycholog Med 1983;13(3): 513-27.
65. Kane J, Honigfeld G, Singer J. Clozapine for the treatment resistant schizophrenic: a double-blind comparison with chlorpromazine. Arch General Psychiatry 1988;45:789-96.
66. Kapur S, Remington G. Dopamine D(2) receptors and their role in atypical antipsychotic action: still necessary and may even be sufficient. Biol Psychiatry 2001;50(11):873-83.
67. Kapur S, Seeman P. Does fast dissociation from the dopamine D(2) receptor explain the action of atypical antipsychotics? A new hypothesis. Am J Psychiatry 2001;158(3):360-9.
68. Karagianis JL, Dawe IC, Thakur A, Raskin J, Roychowdhury SM. Rapid tranquillization with olanzapine in acute psychosis: a case series. J Clin Psychiatry 2001;62(Suppl 2):12-6.
69. Kasper S, Quiner S, Barnas C, Fabisch H, Haushofer M, Sackel C, et al. Zotepine in the treatment of acute hospitalized schizophrenic episodes. Int Clin Psychopharmacol 2001;16(3):163-8.
70. Keck P, Buffenstein A, Ferguson J, Feighner J, Jaffe W, Harrigan EP, et al. Ziprasidone 40 and 120 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: a 4-week placebo-controlled trial. Psychopharmacology 1998;140(2):173-84.
71. King DJ. Drug treatment of the negative symptoms of schizophrenia. Eur Psychopharmacology 1998;8:33-42.
72. Kirov GK, Murray RM, Seth RV, Feeney S. Observations on switching patients with schizophrenia to risperidone treatment. Acta Psychiatr Scand 1997;95:439-43.
73. Kopala LC, Fredrikson D, Good KP, Honer WG. Symptoms in neuroleptic-naive, first episode schizophrenia: response to risperidone. Biol Psychiatry 1996;39:296-8.
74. Kopala LC, Good KP, Fredrikson D, Whitehom D, Lazier L, Honer WG. Risperidone in first-episode schizophrenia: improvement in symptoms and pre-existing extrapyramidal signs. International J Psychiatry Clin Practice 1998;2(Suppl 1):19-25.
75. Kopala LC, Good KP, Honer WG. Extrapyramidal signs and clinical symptoms in first-episode schizophrenia: response to low-dose risperidone. J Clin Psychopharmacol 1997;17(4):308-13.
76. Kopelowicz A, Zarate R, Tripodis K, Gonzalez V, Mintz J. Differential efficacy of olanzapine for deficit and nondeficit negative symptoms in schizophrenia. Am J Psychiatry 2000;157(6):987-93.
77. Lane HY, Chiu WC, Chou JC, Wu ST, Su MH, Chang WH. Risperidone in acutely exacerbated schizophrenia: dosing strategies and plasma levels. J Clin Psychiatry 2000;61(3):209-14.
78. Launer M. Zotepine and nefazadone for clozapine 'reds'. In: Mortimer AM, editor. 2002 [personal communication].
79. Lawler CP, Prioleau C, Lewis MM, Mak C, Jiang D, Schetz JA, et al. Interactions of the novel antipsychotic aripiprazole (OPC-14597) with dopamine and serotonin receptor subtypes. Neuropsychopharmacology 1999;20(6):612-27.
80. Leucht S, Pitschel-Walz G, Abraham D, Kissling W. Efficacy and extrapyramidal side-effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo. A meta-analysis of randomized controlled trials. Schizophrenia Res 1999;35(1):51-68.
81. Leysen JE, Gommeren W, Schotte A. Serotonin receptor subtypes: possible roles and implications in antipsychotic drug action. In: Kane JM, Moller H-J, Awouters F, editors. Serotonin in antipsychotic treatment. New York: Marcel Dekker, Inc; 1996. p. 51-75.
82. Lieberman JA. Atypical antipsychotic drugs as a first-line treatment of schizophrenia: a rationale and hypothesis. J Clin Psychiatry 1996; 57(Suppl 11):68-71.
83. Loo H, Poirer-Littre MF, Theron M. Amisulpiride versus placebo in the medium-term treatment of the negative symptoms of schizophrenia. Br J Psychiatry 1997;170:18-22.
84. Lund BC, Perry PJ, Brooks JM, Arndt S. Clozapine use in patients with schizophrenia and the risk of diabetes, hyperlipidaemia, and hypertension: a claims-based approach. Arch General Psychiatry 2001;58(12):1172-6.
85. Marder SR. Antipsychotic drugs and relapse prevention. Schizophrenia Res 1999;35(Suppl 1):87-92.
86. Marder SR, Meibach RC. Risperidone in the treatment of schizophrenia. Am J Psychiatry 1994;151(6):825-35.
87. Martin C. Impact of olanzapine on quality of life in schizophrenia. Eur Psychiatry 1996;11(Suppl 4):252 [abstract].
88. Matsubayashi H, Amano T, Sasa M. Inhibition by aripiprazole of dopaminergic inputs to striatal neurons from substantia nigra. Psychopharmacologia 1999;146(2):139-43.
89. McAllister-Williams RH, Ferrier IN. Rapid tranquilisation: time for a reappraisal of options for parenteral therapy. Br J Psychiatry 2002; 179(485):489.
90. McManus DQ, Arvanitis LA, Kowalcyk BB. Quetiapine, a novel antipsychotic: experience in elderly patients with psychotic disorders. Seroquel Trial 48 Study Group. J Clin Psychiatry 1999;60(5):292-8.
91. Meyer-Lindenberg A, Gruppe H, Bauer U, Lis S, Krieger S. Improvement of cognitive function in schizophrenic patients receiving clozapine or zotepine: results from a double-blind study. Pharmacopsychiatry 1997;30:35-42.
92. Meyer JM. A retrospective comparison of weight, lipid, and glucose changes between risperidone and olanzapine treated inpatients: metabolic outcomes after 1 year. J Clin Psychiatry 2002;63(5):425-33.
93. Millan MJ, Schreiber R, Monneyron S, Denorme B, Melon C, Queriaux S, et al. S-16924, a novel, potential antipsychotic with marked serotonin1A agonist properties. IV. A drug discrimination comparison with clozapine. J Pharmacol Exp Ther 1999;289(1):427-36.
94. Mir S, Taylor D. Atypical antipsychotics and hyperglycaemia. Int Clin Psychopharmacol 2001;16(2):63-731.
95. Moller H-J. Amisulpride: a review of its efficacy in schizophrenia. Acta Psychiatr Scand 2000;400(Suppl):17-22.
96. Moller H-J, Boyer P, Fleurot O, Rein W. Improvement of acute exacerbations of schizophrenia with amisulpiride: a comparison with haloperidol. Psychopharmacology 1997;132:396-401.
97. Mortimer AM. A clozapine cohort: outcome and issues of concern. Human Psychopharmacol 1997;12:361-3.
98. Newcomer J, Haupt DW, Fucetola R, Melson AK, Schweiger JA, Cooper BP, et al. Abnormalities in glucose regulation during antipsychotic treatment of schizophrenia. Arch General Psychiatry 2002; 59(4):337-45.
99. Parsa A, Bastani B. Quetiapine (Seroquel) in the treatment of psychosis in patients with Parkinson's disease. J Neuropsychiatry Clin Neurosci 1998;10(2):216-9.
100. Petit M, Raniwalla J, Tweed JA, Leutenegger E, Dollfus S, Kelly F. A comparison of an atypical and typical antipsychotic, zotepine versus haloperidol in patients with acute exacerbation of schizophrenia: a parallel-group double-blind trial. Psychopharmacol Bull 1996;32(1): 81-7.
101. Peuskens J, Link CGG. A comparison of quetiapine and chlopromazine in the treatment of schizophrenia. Acta Psychiatr Scand 1997; 96:265-73.
102. Pfizer LTD. Introducing new products to the schizophrenia market. In: Mortimer AM, editor. Data on file, ZEL200/0702. 2002 [personal communication].
103. Pichot P, Boyer P. A double blind, controlled, multi-centre trial of low dose amisulpiride (Solian 50) versus low dose fluphenazine in the treatment of negative symptoms in chronic schizophrenia. Ann Psychiatry 1988;3(3):312-20.
104. Poyurovsky M, Pashinian A, Gil-Ad I, Maayan R, Schneidman M, Fuchs C, et al. Olanzpine-induced weight gain in patients with first-episode schizophrenia: a double-blind, placebo-controlled study of fluoxetine addition. Am J Psychiatry 2002;159(6):1058-60.
105. Procyshyn RM, Zerjav S. Drug utilization patterns and outcomes associated with in-hospital treatment with risperidone or olanzapine. Clin Ther 1998;20(6):1203-17.
106. Raniwalla J, Tweed JA, Dollfus S, Petit M. A comparison of an atypical (zotepine) and classical (haloperidol) antipsychotic in patients with acute exacerbation of schizophrenia. Schizophrenia Res 1996;18(2,3):133.
107. Ray WA, Meador KG. Antipsychotics and sudden death: is thioridazine the only bad actor? Br J Psychiatry 2002;180:483-4.
108. Reeves K, Harrigan EP. The efficacy and safety of two fixed doses of ziprasidone in schizophrenia and schizoaffective disorder. Presented at the 149th annual meeting of the American Psychiatric Association, New York. 1996.
109. Richelson E, Souder T. Binding of antipsychotic drugs to human brain receptors: focus on new generation compounds. Life Sci 2000;68(1): 29-39.
110. Russell JM, Mackell JA. Bodyweight gain associated with atypical antipsychotics: epidemiology and therapeutic implications. CNS Drugs 2001;15(7):537-51.
111. Rymer M, Williets S, Shepherd CJ, Mortimer AM. An audit of antipsychotic prescribing in primary care 2002 [unpublished work].
112. Saletu B, Kufferle B, Grunberger J. Clinical, EEG mapping and psychometric studies in negative schizophrenia: comparative trials with amisulpiride and fluphenazine. Neuropsychobiology 1994;29(3):125-35.
113. Sanger T, Lieberman JA, Tohen M, Grundy S, Beasley CM, Tollefson G. Olanzapine versus haloperidol treatment in first-episode psychosis. Am J Psychiatry 1999;156(1):79-87.
114. Sciolla A, Jeste DV. Use of antipsychotics in the elderly. Int J Psychiatry Clin Practice 1998;2(Suppl 1):27-34.
115. Seeman P. Dopamine/neuroleptic receptors in schizophrenia. In: Burrows GD, Norman TR, Rubinstein G, editors. Handbook on studies of schizophrenia. Amsterdam: Elsevier; 1986.
116. Seeman P. Atypical antipsychotics: mechanism of action. Can J Psychiatry 2002;47(1):27-38.
117. Sernyak MJ, Leslie DL, Alarcon RD, Losonczy M, Rosenheck R. Association of diabetes mellitus with use of atypical neuroleptics in the treatment of schizophrenia. Am J Psychiatry 2002;159(4):561-6.
118. Silver HSN. Augmentation with fluvoxamine but not maprotiline improves negative symptoms in treated schizophrenia: evidence for a specific serotonergic effect from a double-blind study. J Clin Psychopharmacol 1998;18:208-11.
119. Song F. Risperidone in the treatment of schizophrenia: a neta-analysis of randomised controlled trials. J Psychopharmacol 1997;11:65-71.
120. Speller J, Barnes TRE, Curson DA. One-year, low-dose neuroleptic study of in-patients with chronic schizophrenia characterised by persistent negative symptoms: amisulpiride v. haloperidol. Br J Psychiatry 1997;171:564-8.
121. Stahl SM. Selecting an atypical antipsychotic by combining clinical experience with guidelines from clinical trials. J Clin Psychiatry 1999;60(Suppl 10):31-41.
122. Stahl SM. Dopamine system stabilizers, aripiprazole, and the next generation of antipsychotics, part 2: illustrating their mechanism of action. J Clin Psychiatry 2001;62(12):923-4.
123. Stahl SM. Dopamine system stabilizers, aripiprazole, and the next generation of antipsychotics, part 1, "Goldilocks" actions at dopamine receptors. J Clin Psychiatry 2002;62(11):841-2.
124. Sugiyama A, Satoh Y, Hashimoto K. In vivo canine model comparison of cardiohemodynamic and electrophysiological effects of a new antipsychotic drug aripiprazole (OPC-14597) to haloperidol. Toxicol Appl Pharmacol 2001;173(2):120-8.
125. Swift RH, Harrigan EP, van Kammen DP. A comparison of fixed -dose, intramuscular (IM) ziprasidone with flexible-dose, IM haloperidol. Eur Neuropsychopharmacol 1998;8(Suppl 2):216.
126. Tamminga CA. Partial dopamine agonists in the treatment of psychosis. J Neural Transmission-General Section 2002;109(3):411-20.
127. Taylor D. UK prescribing of antipsychotics and clozapine. In: Kerwin RW, editor. The earlier use of clozaril: a discussion. London: The Workhouse; 2002. p. 15-20.
128. Taylor D, McConnell D, McConnell H, Kerwin RW. The Maudsley 2001 prescribing guidelines. 6th ed. London: Martin Dunitz; 2001.
129. Taylor D, Mir S, Mace S, Whiskey E. Co-prescribing of atypical and typical antipsychotics-prescribing sequence and documented outcome. Psychiatric Bull 2002;26:170-2.
130. Taylor DM, McAskill R. Atypical antipsychotics and weight gain-a systematic review. Acta Psychiatr Scand 2000;101:416-32.
131. Tedroff J, Ekesbo A, Sonesson C, Waters N, Carlsson A. Long-lasting improvement following (-)-OSU6162 in a patient with Huntingdon's disease. Neurology 1999;53(7):1605-6.
132. Tedroff J, Torstenson R, Hartvig P, Sonesson C, Waters N, Carlsson A, et al. Effects of the substituted (S)-3-phenylpiperidiine (-)OSU6162 on PET measurements in subhuman primates: evidence for tone-dependent normalization of striatal dopaminergic activity. Synapse 1998;28(4):280-7.
133. The Department of Health. The National Service Framework for Mental Health [bill/resolution]. 1999.
134. The Department of Health HMG. Modemising Mental Health Services: White Paper [bill/resolution]. 1997.
135. The Zito Trust. The practice gap in schizophrenia: are people with schizophrenia being given the best chance in life? Eli Lilly UK [pamphlet]. 2001.
136. Thompson C. The use of high dose antipsychotic medication. Br J Psychiatry 1994;164:448-58.
137. Tollefson G, Sanger T. Negative symptoms: a path analytic approach to a double-blind, placebo- and haloperidol-controlled clinical trial with olanzapine. Am J Psychiatry 1997;154:457-65.
138. Tollefson G, Sanger T, Lu Y, Thieme M. Depressive signs and symptoms in schizophrenia: a prospective blinded trial of olanzapine and haloperidol. Arch General Psychiatry 1998;55:250-8.
139. Tracy JJ, Monaco C, Giovannetti T, Abraham G, Josiassen RC. Anticholinergicity and cognitive processing in chronic schizophrenia. Biol Psychiatry 2001;56(1):1-22.
140. Tran PV, Hamilton SH, Kuntz AJ, Potvin JH, Andersen SW, Beasley Jr C, et al. Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders. J Clin Psychopharmacol 1997;17(5):407-18.
141. Tran P, Shamir E, Poyorovski M, Lokshin P, Weizer N, Dorfman P, et al. Olanzapine in the treatment of patients who failed to respond to or tolerate clozapine. Psychopharmacol Bull 1997;33(3): 599.
142. Tuunainen A, Wahlbeck K, Gilbody SM. Newer antipsychotic medication versus clozapine for schizophrenia. Cochrane Database System Review 2000;2 [CD000966] [generic].
143. Tyson PJ, Mortimer AM, Wheeler JA. High dose antipsychotic treatment in clinical practice: a review, audit and survey of consultant psychiatrist opinions. Psychiatric Bull 1999;23:661-4.
144. Umbricht D, Ames D, Wirshing WC. Predictors of response to clozapine in a long-term double blind treatment study. Schizophrenia Res 1997;24:189.
145. Warner JP, Slade R, Barnes TRE. Change in neuroleptic prescribing practices. Psychiatric Bull 1995;19:237-9.
146. Wassef AA, Dott SG, Harris A, Brown A, O'Boyle M, Meyer WJ, et al. Randomized, placebo-controlled pilot study of divalproex sodium in the treatment of acute exacerbations of chronic schizophrenia. J Clin Psychopharmacol 2000;20(3):357-61.
147. Weiden P, Aquila A, Standard J. Atypical antipsychotic drugs and long-term outcome in schizophrenia. J Clin Psychiatry 1996;57(Suppl 11):53-60.
148. Wetterling T. Bodyweight gain with atypical antipsychotics. A comparative review. Drug Safety 2001;24(1):59-73.
149. World Health Organisation. Prophylactic use of anticholinergics in patients on long-term neuroleptic treatment. Br J Psychiatry 1990; 156:412.
150. Wright P, Birkett M, Meehan K. A double-blind dose response study comparing intramuscular olanzapine, haloperidol and placebo in acutely agitated schizophrenic patients. Schizophrenia Res 2001; 49(Suppl 1):250-1.
151. Wright P, Birkett M, David SR, Meehan K. Double-blind, placebo-controlled comparison of intramuscular olanmzapine and intramuscular haloperidol in the treatment of acute agitation in schizophrenia. Am J Psychiatry 2001;158:1149-51.
152. Zarate CA. Sudden cardiac death and antipsychotics. Arch General Psychiatry 2001;58(1168):1171.
153. Zhang XY, Zhou DF, Cao LY, Zhang PY, Wu GY, Shen YC. Risperidone versus haloperidol in the treatment of acute exacerbations of chronic inpatients with schizophrenia: a randomized double-blind study. Int Clin Psychopharmacol 2001;16(6):325-30.